Autori: Andreas AP
| Naslov | High Doses Of Imatinib Mesylate (800mg/Day) Significantly Improve Rates Of Major And Complete Cytogenetic Remissions (Mcr, Ccr) - Results From The First Planned Interim Analysis Of A Multicenter, Randomised, 2-Arm - Phase Iii Study Comparing Imatinib Standard Dose (400 Mg/Day) With Imatinib High Do (Meeting Abstract) |
| Autori | Andreas AP Boskovic Darinka V Gastl Guenther A |
| Info | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2008), vol. 93 br. , Suppl. Suppl. 1, str. 0406- |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
